BioVaxys Technology (FRA:5LB) Gross Profit : €0.00 Mil (TTM As of Jul. 2024)

BioVaxys Technology Gross Profit Chart

BioVaxys Technology Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Gross Profit	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioVaxys Technology's Gross Profit

For the Biotechnology subindustry, BioVaxys Technology's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVaxys Technology's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Gross Profit distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's Gross Profit falls into.

BioVaxys Technology Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

BioVaxys Technology's Gross Profit for the fiscal year that ended in Oct. 2023 is calculated as

BioVaxys Technology's Gross Profit for the quarter that ended in Jul. 2024 is calculated as

Gross Profit for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

BioVaxys Technology's Gross Margin % for the quarter that ended in Jul. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

BioVaxys Technology  (FRA:5LB) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BioVaxys Technology had a gross margin of N/A% for the quarter that ended in Jul. 2024 => No sustainable competitive advantage

BioVaxys Technology Gross Profit Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description